08.01.25 -- Biopharma Needs A Boost — Our Newest Podcast Has Ideas

Check out the latest episodes from Better Biopharma, Cell & Gene: The Podcast, and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series.

How can the biopharmaceutical industry improve? Join Bioprocess Online's Tyler Menichiello as he explores this question through a series of interviews with experts and leaders from across the space. Subscribe for biweekly, in-depth conversations with the brightest minds in biotech to learn how they're moving the needle to make better medicines and optimize manufacturing.

Lumen Bioscience is putting the farm in biopharma — literally! In this episode of Better Biopharma, Lumen's EVP of production and development, Craig Behnke, Ph.D., explains the company's chlorophyll-powered approach to bioprocessing using photosynthetic cyanobacteria.

Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies (aka 'Epic Bio') explains how epigenetic editing is revolutionizing genetic medicine by controlling gene expression, without cutting DNA like traditional CRISPR technologies.

Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, how he spun his academic discoveries out into a biotech company developing new obesity drugs, and the need for obesity treatments with fewer side effects than currently available GLP-1 therapies.

Dr. Hernan Bazan, M.D., co-founder and CEO at New Orleans-based South Rampart Pharma, talks about building an ultra-lean drug development company to address an unmet need observed in his own patients as a surgeon: safe treatments for acute pain.

Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a radiopharmaceutical company focused on oncology.

George Magrath, CEO of Opus Genetics, shares with Host, Erin Harris, how the company is advancing gene therapies for inherited retinal diseases (IRDs), with a focus on LCA5, a rare and severe form of childhood blindness.

Host Erin Harris talks to Ralf Schmid, Ph.D., Associate Director of Preclinical Research at Novartis Biomedical Research, about the evolving use of large animal models in gene therapy development.